QR12000
/ Createrna
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 15, 2026
A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension
(clinicaltrials.gov)
- P2 | N=391 | Completed | Sponsor: Wuhan Createrna Science and Technology Co., Ltd
New P2 trial • Cardiovascular • Hypertension
January 31, 2026
A multicenter, randomized, double-blind, positive drug parallel-controlled clinical study to evaluate the efficacy and safety of QR12000 Compound Tablets and Sacubitril-Valsartan Sodium Tablets for the treatment of patients with moderate and severe essential hypertension
(ChiCTR)
- P3 | N=810 | Recruiting | Sponsor: Peking University First Hospital; Peking University First Hospital
New P3 trial • Cardiovascular • Hypertension
1 to 2
Of
2
Go to page
1